Brian joined F-Prime Capital in 2018 and focuses primarily on investments in the biopharmaceutical and medical technology sectors. Prior to joining F-Prime, Brian was an engagement manager at McKinsey and Company, where he advised pharmaceutical and medical technology companies on business development, R&D, and strategy topics.
Brian holds a Ph.D. in immunology from Yale University and received his B.S. in biochemistry from the University of Notre Dame.
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Learn more at www.avalynpharma.com.
Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Learn more at www.rallybio.com.